EXECUTIVE INTERVIEW – Noxopharm: Introducing a Novel & Potentially Transformative Drug Candidate in the Treatment of Cancer
Graham Kelly, Founder, Executive Chairman, and CEO of Noxopharm, discusses the company’s innovative approach to cancer treatment.
Emile Youssef, MD, PhD, says due to tumor heterogeneity, the plasticity and diversity of cancer cells, and a multitude of other factors, biomarker development is a challenge, and thus explores four trends in cancer biomarker discovery.
Josef Bossart, PhD, explains how accurately estimating a product’s clinical development timelines is more than simply adding up the individual timelines, almost always optimistic. You need to “know” the numbers, not just calculate them.
OLIGONUCLEOTIDE DELIVERY – Dectin-1 Receptor-Mediated Delivery of Oligonucleotide Drugs Complexed With Schizophyllan Dendritic Cells & Macrophages
Kenji Arima, PhD, and Akihiko Watanabe, PhD, introduce NapaJen Pharma’s technology with a specific focus on solving some of the current challenges of oligonucleotide therapeutics.
Cheryl L. Barton, PhD, and Bianca Piachaud-Moustakis, PhD, believe the role of TIL therapy as an anticancer therapy in melanoma and possibly other solid tumors holds great promise and could become a viable course of treatment in the future.
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
Daniel de Boer, Chief Executive Officer of ProQR, discusses the use of RNA technology to directly target the underlying cause of genetic diseases.
Daniel J. O’Connor believes a trigger mechanism that can turn cold tumors hot can help researchers set their focus on delivering potentially life-saving drugs directly to core of a cancerous tumor.
Fabrice Navarro, PhD, summarizes recent disappointing clinical trial results for HIV vaccines and reports on CEA-Leti’s new approach based on engineered lipid nanoparticles that deliver p24 (a viral protein that optimizes the CpG adjuvant’s effect) with pinpoint accuracy.
Bob Ward, Chairman and CEO at Eloxx Pharmaceuticals, discusses nonsense mutations and how his company’s goal is to bring safe and effective therapies to children and adults suffering from genetic diseases as quickly as possible.
EXCLUSIVE ONLINE CONTENT
Vaccinex, Inc. recently announced the signing of multi-project deals with two undisclosed prominent pharmaceutical companies…..
SIRION Biotech & Sanofi Join Forces to Develop Gene Therapies for Multiple Life-Threatening Disorders
SIRION Biotech GmbH recently announced it signed a license and collaboration agreement with Sanofi to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize….
Catalent to Acquire Delphi Genetics & Launch US Plasmid Manufacturing Site to Establish Global pDNA Development & Manufacturing Capabilities
Catalent and Delphi Genetics recently announced they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics. Catalent is also….
SCYNEXIS, Inc. recently announced it has entered into a licensing agreement and strategic partnership with Hansoh Pharmaceutical Group Company Limited…..
Biomunex Pharmaceuticals Signs Strategic License & Co-development Agreement With Onward Therapeutics
Biomunex Pharmaceuticals and Onward Therapeutics SA recently announced the signing of a strategic exclusive worldwide license and co-development agreement for a proprietary….